<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="566">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04359797</url>
  </required_header>
  <id_info>
    <org_study_id>200727</org_study_id>
    <nct_id>NCT04359797</nct_id>
  </id_info>
  <brief_title>COVID-19 Patient Positioning Pragmatic Trial</brief_title>
  <official_title>Pragmatic Trial Exploring Impact of Patient Positioning in the Management of Patients Infected With COVID-19: Supine vs. Prone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine if provider-recommended guidance on supine (on back) vs. prone
      (on stomach) positioning of patients testing positive for COVID-19 requiring supplemental
      oxygen, but not yet mechanically ventilated, improves outcomes in the inpatient setting. This
      study will be performed as a pragmatic clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Disease Progression and Timing of Intervention The intervention described herein focuses on
      adjustment of patient positioning aimed at improving gas exchange and lung function in
      patients harboring COVID-19. This intervention will target the inpatient setting generally.

      Scientific/Clinical Rationale for Approach Since emergence of the novel coronavirus, severe
      acute respiratory syndrome coronavirus 2 (SARS-CoV-2) now designated coronavirus disease 2019
      (COVID-19), one in six affected patients becomes seriously ill. The lung appears to be the
      most susceptible target organ, with a large swath of symptomatic patients struggling with
      mild upper respiratory tract illness and severe viral pneumonia resulting in respiratory
      failure. This respiratory failure is often fatal, with one study showing 28% non-survivors
      having experienced respiratory failure. Moreover, 81-97% of patients requiring mechanical
      ventilation do not survive.

      Like its interaction with Severe Acute Respiratory Syndrome (SARS-CoV), angiotensin
      converting enzyme 2 (ACE2) is the functional receptor for COVID-19. Viral adherence to
      host-cell membrane associated ACE2 facilitates the proximity required for viral &quot;spike&quot;
      mediated genetic material injection. In COVID-19, this spike is 10-20 times more likely to
      bind ACE2 than SARS. ACE2 is expressed in 0.64% of all human lung cells, with 83% of those
      cells being alveolar epithelial type II. In addition, gene ontology enrichment analysis
      showed that the ACE2-expressing alveolar epithelial type II have high levels of multiple
      viral process-related genes, including regulatory genes for viral processes, viral life
      cycle, viral assembly, and viral genome replication, suggesting that the ACE2-expressing
      alveolar epithelial type II cells facilitate coronaviral replication in the lung. Thus, these
      cells likely serve as a ready reservoir for viral invasion. Perhaps more importantly,
      alveolar type II cells function to generate and recycle surfactant essential to respiratory
      activity. Surfactant defends against alveolar collapse at low lung volume and protects the
      lung from injuries/infections caused by inhaled particles and micro-organisms. In COVID-19,
      if these vital cells are being destroyed, alveolar failure may ensue with severe lung
      impairment. Thus, interventions that are aimed at improving pressure normalization and
      alveolar protection may be beneficial in these patients.

      Prone positioning (PP) has long been used to combat hypoxemia in acute respiratory distress
      syndrome (ARDS). Improvements in gas exchange result from improved alveolar ventilation and
      blood flow redistribution with enhanced perfusion following. PP reduces lung over inflation
      and bolsters alveolar recruitment. PP also promotes uniformity of vertical pleural pressure
      gradients resulting in more uniform alveolar size. Considering these physiologic factors
      together, the investigators hypothesize PP serves to balance stress and strain within the
      lungs of non-critically ill patients with COVID-19 leading to improved outcomes compared to
      traditional supine positioning.

      Prior Research Supporting the Positioning Model:

      Multiple studies have been conducted that support the use of PP as a proactive treatment to
      combat hypoxemia in ARDS. Each year, approximately 170,000 people are diagnosed with ARDS,
      and those diagnosed face mortality rates between 25% and 40%. The use of PP stretches back to
      the 1970s, as providers began to search for ways to ameliorate ARDS symptomatology and reduce
      the then even higher levels of mortality associated with it. Following initial reports that
      PP significantly improved oxygenation in 70-80% of patients with ARDS, it was adopted as a
      standard treatment option. Initially, randomized clinical trials struggled to replicate these
      findings, citing multiple limitations to study enrollment and treatment standardization that
      made ascertaining conclusive results difficult. Only as RCT construction has been refined to
      accommodate for these limitations have the benefits of PP been more clearly demonstrated.

      These beneficial effects have been recently upheld by the landmark PROSEVA study, a
      multicenter, prospective, randomized, controlled trial, that randomly assigned 466 patients
      with severe ARDS to undergo prone-positioning sessions of at least 16 hours or to be left in
      the supine position. Their results demonstrated a significant improvement in both 28- and
      90-day mortality rates: &quot;the 28-day mortality was 16.0% in the prone group and 32.8% in the
      supine group (P&lt;0.001). The hazard ratio for death with prone positioning was 0.39 (95%
      confidence interval [CI], 0.25 to 0.63). Unadjusted 90-day mortality was 23.6% in the prone
      group versus 41.0% in the supine group (P&lt;0.001), with a hazard ratio of 0.44 (95% CI, 0.29
      to 0.67)&quot;.

      Per these positive findings, PP has been consistently shown to be an effective mechanism to
      increase oxygenation in patients with ARDS when implemented under the following conditions:
      early enlisting of treatment and its consistent maintenance for at least 16 hours per day,
      and with concurrent use of lung-protective therapies. Translating these findings towards
      treatment of COVID-19 positive patients seems promising given the similarity of manifested
      symptoms and complications.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 27, 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study will be performed as a pragmatic controlled clinical trial with parallel group assignment.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Patients and providers will necessarily be unblinded, but outcomes will be analyzed by a blind assessor.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Modified WHO Ordinal Scale</measure>
    <time_frame>5 days post-randomization</time_frame>
    <description>The highest level of support on the 5th day after enrollment according to the following scale adjusted for patient status at enrollment according to the same scale and ranked by mean FIO2 within each category, as appropriate.
Death
ECMO
Mechanical ventilation (ranked by mean FIO2)
Non-invasive ventilation such as BiPAP (ranked by mean FIO2)
High flow nasal cannula, e.g. Optiflow, Vapotherm or other similar device (titrated by FiO2%) (ranked by mean FIO2)
Standard nasal cannula (titrated by L/min up to 15 L/min) or face mask (ranked by mean FIO2)
Room air</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FIO2</measure>
    <time_frame>First 5 days post-randomization</time_frame>
    <description>For each day, the investigators will record the most intensive oxygen delivery mode and then, for that highest level of oxygen support device, the max FiO2 while exposed to that device.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to this arm will remain in their natural choice of position, which is anticipated to favor a supine, semi-recumbent position.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to this arm will be encouraged to lay in a completely prone position for as much time as is tolerable during hospitalization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Prone</intervention_name>
    <description>Provider-recommended guidance on prone positioning of patients</description>
    <arm_group_label>Prone</arm_group_label>
    <other_name>Proning</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>No provider-recommendation, patients will remain in their natural choice of position</description>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  This study will enroll all patients admitted to VUMC who test positive for COVID-19
             and require supplemental oxygen, but are not yet mechanically ventilated.

        Exclusion Criteria:

          -  Patients admitted on mechanical ventilation will be excluded from enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd W Rice, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Q&amp;A on coronaviruses (COVID-19) [Internet]. [cited 2020 Mar 24];Available from: https://www.who.int/news-room/q-a-detail/q-a-coronaviruses</citation>
  </reference>
  <reference>
    <citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038.</citation>
    <PMID>32171076</PMID>
  </reference>
  <reference>
    <citation>Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24. Erratum in: Lancet Respir Med. 2020 Apr;8(4):e26.</citation>
    <PMID>32105632</PMID>
  </reference>
  <reference>
    <citation>Feb 24 SS| NR| CN|, 2020. Study of 72,000 COVID-19 patients finds 2.3% death rate [Internet]. CIDRAP. [cited 2020 Mar 24];Available from: http://www.cidrap.umn.edu/news-perspective/2020/02/study-72000-covid-19-patients-finds-23-death-rate</citation>
  </reference>
  <reference>
    <citation>Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3.</citation>
    <PMID>32015507</PMID>
  </reference>
  <reference>
    <citation>Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020 Mar 13;367(6483):1260-1263. doi: 10.1126/science.abb2507. Epub 2020 Feb 19.</citation>
    <PMID>32075877</PMID>
  </reference>
  <reference>
    <citation>Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-Cell RNA Expression Profiling of ACE2, the Receptor of SARS-CoV-2. Am J Respir Crit Care Med. 2020 Sep 1;202(5):756-759. doi: 10.1164/rccm.202001-0179LE.</citation>
    <PMID>32663409</PMID>
  </reference>
  <reference>
    <citation>Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020 Apr;46(4):586-590. doi: 10.1007/s00134-020-05985-9. Epub 2020 Mar 3.</citation>
    <PMID>32125455</PMID>
  </reference>
  <reference>
    <citation>Andreeva AV, Kutuzov MA, Voyno-Yasenetskaya TA. Regulation of surfactant secretion in alveolar type II cells. Am J Physiol Lung Cell Mol Physiol. 2007 Aug;293(2):L259-71. Epub 2007 May 11. Review.</citation>
    <PMID>17496061</PMID>
  </reference>
  <reference>
    <citation>Johnson NJ, Luks AM, Glenny RW. Gas Exchange in the Prone Posture. Respir Care. 2017 Aug;62(8):1097-1110. doi: 10.4187/respcare.05512. Epub 2017 May 30. Review.</citation>
    <PMID>28559471</PMID>
  </reference>
  <reference>
    <citation>Galiatsou E, Kostanti E, Svarna E, Kitsakos A, Koulouras V, Efremidis SC, Nakos G. Prone position augments recruitment and prevents alveolar overinflation in acute lung injury. Am J Respir Crit Care Med. 2006 Jul 15;174(2):187-97. Epub 2006 Apr 27.</citation>
    <PMID>16645177</PMID>
  </reference>
  <reference>
    <citation>Kallet RH. A Comprehensive Review of Prone Position in ARDS. Respir Care. 2015 Nov;60(11):1660-87. doi: 10.4187/respcare.04271. Review.</citation>
    <PMID>26493592</PMID>
  </reference>
  <reference>
    <citation>Scholten EL, Beitler JR, Prisk GK, Malhotra A. Treatment of ARDS With Prone Positioning. Chest. 2017 Jan;151(1):215-224. doi: 10.1016/j.chest.2016.06.032. Epub 2016 Jul 8. Review.</citation>
    <PMID>27400909</PMID>
  </reference>
  <reference>
    <citation>Gu√©rin C, Reignier J, Richard JC, Beuret P, Gacouin A, Boulain T, Mercier E, Badet M, Mercat A, Baudin O, Clavel M, Chatellier D, Jaber S, Rosselli S, Mancebo J, Sirodot M, Hilbert G, Bengler C, Richecoeur J, Gainnier M, Bayle F, Bourdin G, Leray V, Girard R, Baboi L, Ayzac L; PROSEVA Study Group. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013 Jun 6;368(23):2159-68. doi: 10.1056/NEJMoa1214103. Epub 2013 May 20.</citation>
    <PMID>23688302</PMID>
  </reference>
  <reference>
    <citation>Pickham D, Berte N, Pihulic M, Valdez A, Mayer B, Desai M. Effect of a wearable patient sensor on care delivery for preventing pressure injuries in acutely ill adults: A pragmatic randomized clinical trial (LS-HAPI study). Int J Nurs Stud. 2018 Apr;80:12-19. doi: 10.1016/j.ijnurstu.2017.12.012. Epub 2017 Dec 30.</citation>
    <PMID>29331656</PMID>
  </reference>
  <reference>
    <citation>Schutt SC, Tarver C, Pezzani M. Pilot study: Assessing the effect of continual position monitoring technology on compliance with patient turning protocols. Nurs Open. 2017 Oct 26;5(1):21-28. doi: 10.1002/nop2.105. eCollection 2018 Jan.</citation>
    <PMID>29344391</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 20, 2020</study_first_submitted>
  <study_first_submitted_qc>April 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Todd Rice</investigator_full_name>
    <investigator_title>MD, MSc, Associate Professor, Department of Medicine</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported will be made available (including data dictionaries) after de-identification.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>The data will become available 3 months following publication of outcomes and will remain available for at least 5 years.</ipd_time_frame>
    <ipd_access_criteria>Data will be made available to researchers who provide a methodologically sound proposal that has been approved by the Vanderbilt Institutional Review Board and the study executive committee.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

